Core Viewpoint - Crispr Therapeutics Inc's stock rally in June is showing signs of reversal, with shares down 0.6% at $42.69, indicating a potential end to a seven-day winning streak and a historically bearish signal on the charts [1]. Group 1: Stock Performance - The stock has approached its 260-day moving average, currently within 0.75 of the trendline's 20-day average true range (ATR), after spending at least 80% of the last 10 days and two months below this average [2]. - Historical data shows that after similar signals in the past three years, CRSP was lower one month later 80% of the time, averaging an 8% loss, which could bring shares below the $40 level [3]. Group 2: Options Activity - There has been significant bullish activity in options for Crispr Therapeutics, with a ratio of 14.50 calls bought for every put in the last two weeks, indicating a higher level of optimism than 99% of readings from the past year [5].

Shares of GitLab Inc (NASDAQ:GTLB) are deep in the red this morning, off 10% at $43.68, after software company's disappointing second quarter and full-year guidance overshadowed a first-quarter earnings beat. No fewer than 14 brokerages have chimed in price-target cuts, the steepest coming from JPMorgan Securities to $52 from $58.Today's bear gap has the software stock eyeing its worst single-session drop since April 3. With a now 22% year-to-date deficit, shares of GTLB remain under the pressure of the ove ...

Core Insights - Chewy Inc reported a first-quarter earnings miss despite beating revenue expectations, leading to a lackluster full-year outlook [1] - The stock is experiencing its third consecutive loss and its worst day since August 2023, trading down 11.3% to $40.63 [1][2] - Short interest in the stock has increased by 17.7% over the last two reporting periods, with 14.80 million shares sold short, representing 7.8% of the available float [2] Stock Performance - The stock is pulling back from a two-year high of $48.62 reached on June 6, 2023, but may find support at the 40-day moving average [2] - Despite recent losses, the stock still has a 21% lead for 2025 [2] Options Market Activity - Options traders are leaning bearish, as indicated by a 10-day put/call volume ratio of 1.50, ranking in the 98th percentile of annual readings [3] - Options volume is significantly higher than average, with 13,000 calls and 19,000 puts traded, indicating increased trading activity [4] - The most popular options contracts include the weekly 6/13 40-strike put and the 47-strike put, with new positions being opened at the latter [4]

Group 1 - The core focus of Quad 7 Capital is to provide investment opportunities through their BAD BEAT Investing platform, emphasizing both long and short trades [1] - The team consists of 7 analysts with diverse expertise in business, policy, economics, mathematics, game theory, and sciences, aiming to educate investors on proficient trading [1] - Since May 2020, the company has maintained an average position of 95% long and 5% short, showcasing their strategic approach to market conditions [1] Group 2 - BAD BEAT Investing offers various benefits, including weekly well-researched trade ideas, access to multiple chat rooms, and daily summaries of key analyst upgrades and downgrades [2] - The platform also provides education on basic options trading and extensive trading tools to enhance investor knowledge and skills [2]

Company Overview - Elanco Animal Health Incorporated (ELAN) is currently experiencing significant activity in the options market, particularly with the Jan 16, 2026 $3.00 Call option showing high implied volatility, indicating potential for a major price movement [1] Market Sentiment - The high implied volatility suggests that investors are anticipating a significant price change for Elanco Animal Health shares, which could be driven by an upcoming event [2][4] - Analysts have a mixed outlook on Elanco, with the company holding a Zacks Rank 3 (Hold) in the Medical - Outpatient and Home Healthcare industry, which is in the top 26% of the Zacks Industry Rank [3] Earnings Estimates - Over the past 60 days, there have been no increases in earnings estimates for the current quarter, while six analysts have lowered their estimates, resulting in a decrease of the Zacks Consensus Estimate from earnings of 25 cents per share to 20 cents [3]

Core Insights - Lululemon Athletica Inc's stock has dropped 19.7% to $265.71 due to fiscal second-quarter and full-year guidance that missed expectations, primarily attributed to tariff pressures [1] - The stock is experiencing its worst day since March 2020, reaching its lowest level since April and breaking below the $310 support level [2] - Year-to-date, Lululemon has lost 30% of its value, with short interest accounting for 5.4% of the equity's available float [2] Price Target Adjustments - At least 12 brokerages have reduced their price targets for Lululemon, with BMO making the most significant cut from $302 to $250 [1] Options Activity - Today's options activity shows 46,000 calls and 26,000 puts traded, which is 24 times the typical volume [3] - The most popular option is the weekly 6/6 260-strike put, with positions being opened ahead of expiration [3] Sentiment Indicators - Lululemon's put/call open interest ratio (SOIR) stands at 1.31, placing it in the 97th percentile of annual readings, indicating heightened pessimism among short-term options traders [4] - The company has historically exceeded options traders' volatility expectations, reflected in a Schaeffer's Volatility Scorecard (SVS) of 96 out of 100 [4]

Core Insights - BAD BEAT Investing, led by Quad 7 Capital, has been providing investment opportunities for nearly 12 years, focusing on both long and short trades [1] - The team is recognized for their February 2020 recommendation to sell everything and go short, maintaining an average position of 95% long and 5% short since May 2020 [1] - The investment strategy emphasizes short- and medium-term investments, income generation, special situations, and momentum trades [1] Group 1 - The company comprises a team of 7 analysts with diverse expertise in business, policy, economics, mathematics, game theory, and sciences [1] - BAD BEAT Investing aims to educate investors to become proficient traders through a comprehensive playbook, providing in-depth research with clear entry and exit targets [1] - The firm has a proven track record of success in its investment strategies [1] Group 2 - Benefits of BAD BEAT Investing include understanding market dynamics, executing well-researched trade ideas weekly, and access to multiple chat rooms [2] - Subscribers receive daily summaries of key analyst upgrades and downgrades, along with learning opportunities in basic options trading and access to extensive trading tools [2]

Casino stock Wynn Resorts Inc (NASDAQ:WYNN) is trading 1.9% lower at $88.83 at last check, starting off June on a sour note. The shares are eyeing their fourth-straight loss, extending a pullback from their May 15 five-month highs, and testing support at the $90 level today. Plus, if past is precedent, WYNN could be due for even more losses. Schaeffer's Senior Quantitative Analyst Rocky White compiled a list of the 25 worst S&P 500 Index (SPX) stocks to own in June, going back a decade, and Wynn Resorts sto ...

Core Insights - UnitedHealth Group Inc (NYSE:UNH) has experienced a significant decline of 39.1% year-to-date in 2025, primarily due to rising medical costs and the unexpected departure of CEO Andrew Witty [1] - Despite the challenges, options trading activity remains robust, with a notable volume of both calls and puts in recent trading sessions [2] Options Trading Activity - Over the last 10 trading days, UnitedHealth recorded a total of 4,843,914 options, comprising 3,313,688 calls and 1,530,226 puts [2][3] - The most popular options contract was the weekly 5/23 300-strike call, indicating strong interest among traders [2] Stock Performance - UnitedHealth shares were last observed at $307.50, reflecting a 1.9% increase and marking a potential fourth consecutive daily gain [5] - The stock is attempting to recover from a significant dip to $269.13 on May 16, which was its lowest level since April 2020 [5] Volatility Metrics - The Schaeffer's Volatility Scorecard (SVS) for UnitedHealth ranks at 95 out of 100, suggesting that the stock typically exceeds options traders' annual volatility expectations [7]

Group 1 - BWX Technologies Inc (NYSE:BWXT) shares are currently supported at their March and July 2024 highs, breaking above resistance in the $110-$111 range [2] - All daily moving averages for BWXT are trending upwards, potentially providing a support level in case of a market pullback [2] - Short interest for BWXT has increased by 38.7% in the last two reporting periods, suggesting that a reversal of this pessimism could benefit the stock [3] Group 2 - Aggressive put sellers are active at the June 105-strike, while also purchasing June 120- and 130-strike calls, indicating bullish sentiment [3] - The Schaeffer's open interest ratio (SOIR) for BWXT is at 1.23, historically associated with price bottoms [3] - The Schaeffer's Volatility Index (SVI) for BWXT is at 29%, ranking in the 26th percentile of its annual range, indicating low volatility expectations among options traders [4] Group 3 - The recommended call option for BWXT has a leverage ratio of 6.4, which could double with a 16% gain in the underlying stock [4]